Progenics Pharmaceuticals (PGNX) stock price, revenue, and financials

Progenics Pharmaceuticals market cap is $355 m, and annual revenue was $34.99 m in FY 2019

$355 M

PGNX Mkt cap, 26-Jun-2020

$6.2 M

Progenics Pharmaceuticals Revenue Q1, 2020
Progenics Pharmaceuticals Gross profit (Q1, 2020)4.7 M
Progenics Pharmaceuticals Gross profit margin (Q1, 2020), %75.1%
Progenics Pharmaceuticals Net income (Q1, 2020)-16.8 M
Progenics Pharmaceuticals EBIT (Q1, 2020)-15.9 M
Progenics Pharmaceuticals Cash, 31-Mar-202029.5 M
Progenics Pharmaceuticals EV378.4 M

Progenics Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

74.4m2.2m1.8m1.1m2.2m1.8m867.0k1.8m1.5m41.7m248.0k1.9m1.4m2.5m8.5m53.9m2.3m2.7m3.2m3.9m5.3m4.3m10.0m5.6m6.2m

Cost of goods sold

493.0k1.3m1.6m

Gross profit

9.5m4.3m4.7m

Gross profit Margin, %

95%77%75%

R&D expense

88.0k40.0k8.0m7.6m8.7m10.1m7.9m6.9m7.8m6.7m6.5m6.4m6.8m9.1m8.0m9.8m10.0m10.3m8.1m9.3m8.1m12.4m13.1m11.4m10.4m

General and administrative expense

5.0m3.7m4.0m4.0m4.3m3.4m3.1m3.9m4.3m3.9m3.6m6.0m4.4m5.8m5.6m7.2m5.7m6.0m6.7m7.6m7.1m9.2m14.6m11.5m10.5m

Operating expense total

5.0m3.8m12.0m13.4m14.5m14.9m11.0m10.8m12.1m10.6m10.1m12.4m11.2m15.0m13.6m17.0m15.7m16.3m14.8m16.9m15.2m21.6m28.6m22.4m20.6m

Depreciation and amortization

179.0k144.0k134.0k142.0k132.0k129.0k137.0k

EBIT

55.5m(13.1m)(10.7m)(11.3m)(11.3m)(12.3m)(10.5m)(9.3m)(11.1m)36.7m(10.3m)(11.7m)(10.0m)(12.7m)(5.7m)36.2m(15.3m)(14.3m)(12.4m)(14.3m)(25.0m)(18.2m)(19.1m)(18.1m)(15.9m)

EBIT margin, %

75%(589%)(590%)(1013%)(506%)(681%)(1212%)(514%)(751%)88%(4140%)(604%)(718%)(519%)(67%)67%(650%)(530%)(389%)(370%)(471%)(426%)(192%)(323%)(254%)

Interest expense

16.0k15.0k14.0k14.0k14.0k10.0k12.0k12.0k13.0k12.0k12.0k11.0k10.0k43.0k54.0k79.0k1.1m1.0m1.0m930.0k762.0k500.0k607.0k726.0k915.0k

Interest income

16.0k15.0k14.0k14.0k14.0k10.0k12.0k12.0k13.0k12.0k12.0k11.0k10.0k43.0k54.0k79.0k

Pre tax profit

(11.1m)36.7m(11.7m)(10.0m)(15.3m)(25.8m)(19.7m)(18.8m)

Income tax expense

(1.0k)(227.0k)(96.0k)(1.5m)

Net Income

55.5m(13.1m)(10.7m)(11.3m)(11.3m)(12.3m)(10.5m)(9.3m)(11.1m)37.0m(10.3m)(11.7m)(10.0m)(12.7m)(5.6m)36.3m(16.4m)(16.6m)(15.4m)(13.4m)(15.2m)(24.4m)(18.7m)(19.7m)(18.8m)(16.8m)

Progenics Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

70.1m58.8m65.9m119.3m74.1m138.9m90.6m137.7m42.0m

Accounts Receivable

1.5m6.9m2.9m109.0k3.5m4.9m4.0m3.8m16.0m

Prepaid Expenses

1.7m1.9m2.5m5.6m2.3m2.6m

Inventories

Current Assets

72.5m67.5m70.7m121.9m83.3m148.1m96.9m144.1m63.7m

PP&E

4.0m3.4m2.4m2.6m2.4m4.8m4.1m3.9m11.7m

Goodwill

7.7m7.7m13.1m13.1m13.1m13.1m17.8m

Total Assets

80.1m76.3m114.5m161.0m131.3m199.0m146.0m169.5m119.5m

Accounts Payable

6.3m229.0k793.0k1.0m452.0k567.0k3.4m444.0k1.2m

Short-term debt

2.4m5.4m7.7m

Current Liabilities

6.7m8.7m6.6m6.7m9.7m16.4m15.4m23.4m22.1m

Long-term debt

47.2m39.2m46.9m

Total Debt

47.2m39.2m54.6m

Total Liabilities

8.3m9.7m35.6m36.1m40.6m94.2m82.5m68.4m72.9m

Common Stock

44.0k61.0k79.0k91.0k91.0k93.0k110.0k113.0k

Preferred Stock

Additional Paid-in Capital

463.4m493.6m548.5m589.8m594.5m598.1m609.8m713.0m727.1m

Retained Earnings

(388.7m)(424.1m)(466.7m)(462.3m)(501.4m)(490.6m)(541.6m)(609.2m)(677.8m)

Total Equity

71.8m66.6m79.0m124.9m90.7m104.8m63.5m101.1m46.6m

Debt to Equity Ratio

0.7 x0.4 x

Debt to Assets Ratio

0.3 x0.2 x

Financial Leverage

1.1 x1.1 x1.5 x1.3 x1.4 x1.9 x2.3 x1.7 x2.6 x

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

82.4m56.1m47.8m41.1m55.3m79.2m75.6m94.0m85.3m85.2m108.4m99.3m90.4m65.7m60.1m98.9m126.3m114.0m98.3m83.4m87.5m148.9m109.6m84.8m64.5m29.5m

Accounts Receivable

5.5m2.4m2.1m1.1m1.6m1.3m754.0k817.0k1.5m41.7m152.0k1.4m1.5m2.4m3.6m3.9m2.1m2.7m2.6m3.5m3.8m5.8m4.9m10.6m6.2m6.2m

Prepaid Expenses

1.1m1.2m1.8m1.5m1.2m2.8m1.9m2.0m3.0m2.6m6.0m5.1m5.3m3.8m3.7m3.3m1.7m2.5m2.2m2.2m3.1m4.8m5.1m

Current Assets

89.0m59.5m51.0m43.4m58.6m81.9m77.6m97.7m88.8m131.1m111.6m103.4m97.9m73.2m69.0m106.6m132.1m119.9m102.6m91.8m93.5m156.9m117.6m100.2m75.8m40.5m

PP&E

4.9m4.0m3.9m3.7m3.4m2.7m2.5m2.3m2.2m2.3m2.5m2.5m2.4m2.3m3.7m3.9m4.7m4.6m4.4m3.9m4.1m4.0m6.1m7.0m9.3m14.7m

Goodwill

7.7m7.7m7.7m7.7m7.7m7.7m13.1m13.1m13.1m13.1m13.1m13.1m13.1m13.1m13.1m17.8m17.8m17.8m17.8m

Total Assets

97.6m66.9m58.3m50.5m105.3m127.0m122.5m141.4m132.4m172.1m150.6m142.4m136.9m121.0m118.2m156.9m182.9m170.5m152.9m140.7m142.5m182.4m164.2m152.8m130.1m98.3m

Accounts Payable

6.0m4.1m197.0k125.0k1.9m859.0k234.0k307.0k186.0k566.0k1.3m534.0k2.3m1.5m1.1m1.1m971.0k1.1m1.1m1.6m548.0k629.0k564.0k272.0k674.0k2.9m

Short-term debt

1.2m1.8m4.7m4.8m8.2m6.1m5.8m6.4m7.9m

Current Liabilities

6.4m4.4m4.3m6.8m8.4m6.2m6.1m4.1m4.4m6.2m5.4m6.6m9.9m11.4m13.4m13.8m14.4m16.5m13.1m14.3m14.8m16.5m24.4m23.6m20.1m19.1m

Long-term debt

48.9m48.3m47.8m45.0m42.9m38.3m52.4m51.7m49.6m45.0m

Total Debt

48.9m48.3m47.8m45.0m42.9m38.3m37.6m36.3m34.5m52.9m

Total Liabilities

8.2m5.5m5.4m7.9m38.0m35.7m35.6m33.5m34.2m36.3m35.1m37.1m40.2m42.5m44.4m45.9m93.6m96.0m92.8m80.0m79.7m67.5m80.8m80.1m74.1m67.7m

Common Stock

44.0k44.0k44.0k44.0k67.0k78.0k79.0k91.0k91.0k91.0k91.0k91.0k91.0k91.0k91.0k91.0k92.0k92.0k92.0k95.0k97.0k110.0k110.0k112.0k112.0k113.0k

Preferred Stock

Additional Paid-in Capital

458.9m466.1m468.4m469.4m505.6m541.8m547.9m586.7m588.1m588.8m590.6m592.2m593.5m595.1m596.1m597.0m598.9m600.8m601.7m619.0m635.7m712.1m714.1m724.0m725.4m728.1m

Retained Earnings

(366.5m)(401.8m)(412.5m)(423.8m)(435.4m)(447.6m)(458.1m)(476.0m)(487.1m)(450.1m)(472.5m)(484.2m)(494.2m)(514.0m)(519.7m)(483.4m)(506.9m)(523.6m)(538.9m)(555.0m)(570.1m)(594.5m)(627.9m)(647.6m)(666.5m)(694.6m)

Total Equity

89.5m61.4m53.0m42.6m67.3m91.3m86.9m107.9m98.2m135.8m115.5m105.3m96.7m78.5m73.8m111.0m89.3m74.6m60.1m60.6m62.8m114.9m83.4m72.7m55.9m30.6m

Debt to Equity Ratio

0.5 x0.6 x0.8 x0.7 x0.7 x0.3 x0.5 x0.5 x0.6 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.3 x0.3 x0.2 x0.2 x0.2 x0.3 x

Financial Leverage

1.1 x1.1 x1.1 x1.2 x1.6 x1.4 x1.4 x1.3 x1.3 x1.3 x1.3 x1.4 x1.4 x1.5 x1.6 x1.4 x2 x2.3 x2.5 x2.3 x2.3 x1.6 x2 x2.1 x2.3 x3.2 x

Progenics Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

32.6m(13.1m)(23.8m)(35.1m)(11.3m)(23.5m)(34.0m)(9.3m)(20.4m)(10.3m)(22.0m)(32.0m)(12.7m)(18.3m)18.0m(16.4m)(33.0m)(48.3m)(13.4m)(28.6m)(53.0m)(18.7m)(38.4m)(57.3m)(16.8m)

Depreciation and Amortization

1.1m472.0k772.0k1.1m277.0k595.0k774.0k144.0k277.0k132.0k261.0k398.0k698.0k1.5m1.9m256.0k544.0k832.0k286.0k590.0k1.0m557.0k1.2m1.8m742.0k

Accounts Receivable

3.2m887.0k(580.0k)387.0k5.4m(5.7m)(6.2m)(2.1m)(1.4m)43.0k1.3m1.4m(1.2m)20.0k(403.0k)2.8m2.1m2.2m491.0k164.0k(1.8m)(1.1m)(6.8m)(2.4m)9.8m

Inventories

(2.1m)(2.3m)968.0k

Accounts Payable

(3.6m)(2.2m)(2.3m)155.0k(630.0k)(2.5m)(2.6m)(2.5m)(2.3m)(1.3m)(54.0k)3.3m1.2m733.0k770.0k402.0k557.0k527.0k(1.8m)(2.8m)(2.7m)124.0k(169.0k)240.0k1.6m

Cash From Operating Activities

32.2m(13.8m)(22.1m)(28.9m)(5.6m)(17.5m)(26.4m)(9.3m)(18.0m)(10.9m)(19.9m)(29.7m)(8.0m)(11.5m)27.3m(12.7m)(25.4m)(41.0m)(14.3m)(25.2m)(37.8m)(18.5m)(38.7m)(55.9m)(7.6m)

Purchases of PP&E

(92.0k)(518.0k)(731.0k)(759.0k)(35.0k)(47.0k)(77.0k)(10.0k)(68.0k)(53.0k)(233.0k)(274.0k)(607.0k)(2.7m)(3.3m)(145.0k)(240.0k)(263.0k)(16.0k)(502.0k)(595.0k)(491.0k)(1.8m)(4.5m)(3.6m)

Cash From Investing Activities

8.0k(294.0k)(368.0k)(291.0k)2.0m3.0m3.1m36.0k8.0k(51.0k)(216.0k)(228.0k)(494.0k)(2.4m)(2.9m)(113.0k)(203.0k)(226.0k)(16.0k)(502.0k)(595.0k)(8.5m)(10.1m)(12.7m)(3.6m)

Long-term Borrowings

(2.2m)(3.4m)(1.0m)(2.6m)(3.9m)(1.7m)

Cash From Financing Activities

2.3m82.0k172.0k196.0k(42.0k)34.8m40.1m37.5m37.5m61.0k116.0k1.0m11.0k510.0k232.0k564.0k491.0k9.5m22.6m96.7m(1.0m)(2.3m)(2.6m)(1.5m)

Net Change in Cash

34.5m(14.0m)(22.3m)(29.0m)(3.6m)20.4m16.8m28.2m19.5m(10.9m)(20.0m)(28.9m)(8.4m)(14.0m)24.8m(12.6m)(24.9m)(40.6m)(7.2m)(3.1m)58.2m(28.1m)(52.9m)(73.2m)(12.5m)

Interest Paid

1.1m2.1m3.1m939.0k

Progenics Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.1 x

Progenics Pharmaceuticals Employee Rating

2.512 votes
Culture & Values
3.2
Work/Life Balance
2.8
Senior Management
2.7
Salary & Benefits
3.3
Career Opportunities
2.6
Source